TPP Poised to Improve, Not Diminish, Health Outcomes Across Asia-Pacific Nations

It’s important to remember that innovation doesn’t occur in a vacuum, and that the generics industry—which by definition could not exist but for innovators assuming the risks of developing novel new drugs—relies on innovative biopharmaceutical companies for its success. Striking the appropriate balance between allowing innovation to flourish and ensuring a healthy generics industry is at the heart of U.S. policy, and that should be reflected in the TPP, writes Stephen Ezell in Innovation Files. If the TPP is going to live up to its full promise, the United States cannot afford to back down from its positions on intellectual property issues at this point in the negotiations.